1. Home
  2. EVTC vs NUVB Comparison

EVTC vs NUVB Comparison

Compare EVTC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evertec Inc.

EVTC

Evertec Inc.

HOLD

Current Price

$28.06

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.46

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTC
NUVB
Founded
1988
2018
Country
United States
United States
Employees
N/A
291
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
EVTC
NUVB
Price
$28.06
$4.46
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$35.80
$11.38
AVG Volume (30 Days)
425.2K
3.8M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
0.72%
N/A
EPS Growth
27.17
N/A
EPS
2.20
N/A
Revenue
$453,869,000.00
N/A
Revenue This Year
$12.68
$190.15
Revenue Next Year
$6.86
$62.54
P/E Ratio
$12.63
N/A
Revenue Growth
11.48
N/A
52 Week Low
$24.95
$1.57
52 Week High
$38.56
$9.75

Technical Indicators

Market Signals
Indicator
EVTC
NUVB
Relative Strength Index (RSI) 49.24 44.62
Support Level $27.59 $4.07
Resistance Level $30.25 $5.55
Average True Range (ATR) 1.05 0.21
MACD -0.09 0.07
Stochastic Oscillator 31.80 69.23

Price Performance

Historical Comparison
EVTC
NUVB

About EVTC Evertec Inc.

Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: